QIAGEN N.V. (QGEN) stock
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$49.75−0.06 (-0.12%)
Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%
Qiagen r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $187.52M, down 3.1% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $198.51M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.52M | -3.1% |
| FY2024 | Dec 31, 2024 | $193.49M | -2.5% |
| FY2023 | Dec 31, 2023 | $198.51M | +4.6% |
| FY2022 | Dec 31, 2022 | $189.86M | -0.1% |
| FY2021 | Dec 31, 2021 | $189.96M | +27.4% |
| FY2020 | Dec 31, 2020 | $149.07M | -5.3% |
| FY2019 | Dec 31, 2019 | $157.45M | -2.7% |
| FY2018 | Dec 31, 2018 | $161.85M | +5.0% |
| FY2017 | Dec 31, 2017 | $154.08M | +2.8% |
| FY2016 | Dec 31, 2016 | $149.84M | +2.1% |
| FY2015 | Dec 31, 2015 | $146.83M | -10.3% |
| FY2014 | Dec 31, 2014 | $163.67M | +12.0% |
| FY2013 | Dec 31, 2013 | $146.07M | +19.3% |
| FY2012 | Dec 31, 2012 | $122.48M | -6.2% |
| FY2011 | Dec 31, 2011 | $130.64M | +3.6% |
| FY2010 | Dec 31, 2010 | $126.04M | +16.8% |
| FY2009 | Dec 31, 2009 | $107.90M | +10.9% |
| FY2008 | Dec 31, 2008 | $97.33M | – |
See a number that looks wrong?